We have located links that may give you full text access.
COMPARATIVE STUDY
JOURNAL ARTICLE
Mucin-hypersecreting tumors of the pancreas: assessing the grade of malignancy preoperatively.
American Journal of Surgery 1996 April
BACKGROUND: Mucin-hypersecreting tumor of the pancreas (MHST) is a unique variant of pancreatic tumor, where mucin was excreted from the patulous orifice of the enlarged ampulla of Vater and the main pancreatic duct was dilated with excessive mucin. It is difficult to differentiate preoperatively between benign and malignant variants.
PATIENTS AND METHODS: A total of 18 patients with an MHST were retrospectively reviewed to identify possible indicators of malignancy. The 18 tumors consisted of 9 benign lesions (hyperplasia or adenoma with mild to moderate atypia), 2 borderline disorders (adenoma with severe atypia), and 7 malignant diseases (unequivocal adenocarcinoma).
RESULTS: The age, sex, and site of origin demonstrated no significant difference among the three groups. One of the 9 patients with the benign lesion was diabetic, while 4 of the 7 patients with the malignant variant were diabetic (P<0.05). All 9 benign lesions were confined to the side branch, while 4 of the 7 malignant diseases were located in the main pancreatic duct (P<0.05). The mean greatest diameters of these three variants were 3.2 cm, 3.3 cm, and 6.6 cm, respectively. The mean greatest diameter of the main pancreatic duct in the 7 malignant disorders were larger than in the 9 benign conditions (9.7 versus 5.4 mm, P <0.05). The mean diameter of the mural nodules in the 7 malignant tumors were larger than in the 9 benign lesions (20.5 versus 5.1 mm, P <0.05). The serum and mucin carcinoembryonic antigen and carbohydrate antigen 19-9 levels showed no substantial difference between the benign and malignant variants.
CONCLUSIONS: The presence of diabetes, large tumors (> or = 5 cm), marked dilatation of the main pancreatic duct (> or = 10 mm), main pancreatic duct type, and large mural nodules (> or = 10 mm) is strongly suggestive of a malignant variant of the MHST.
PATIENTS AND METHODS: A total of 18 patients with an MHST were retrospectively reviewed to identify possible indicators of malignancy. The 18 tumors consisted of 9 benign lesions (hyperplasia or adenoma with mild to moderate atypia), 2 borderline disorders (adenoma with severe atypia), and 7 malignant diseases (unequivocal adenocarcinoma).
RESULTS: The age, sex, and site of origin demonstrated no significant difference among the three groups. One of the 9 patients with the benign lesion was diabetic, while 4 of the 7 patients with the malignant variant were diabetic (P<0.05). All 9 benign lesions were confined to the side branch, while 4 of the 7 malignant diseases were located in the main pancreatic duct (P<0.05). The mean greatest diameters of these three variants were 3.2 cm, 3.3 cm, and 6.6 cm, respectively. The mean greatest diameter of the main pancreatic duct in the 7 malignant disorders were larger than in the 9 benign conditions (9.7 versus 5.4 mm, P <0.05). The mean diameter of the mural nodules in the 7 malignant tumors were larger than in the 9 benign lesions (20.5 versus 5.1 mm, P <0.05). The serum and mucin carcinoembryonic antigen and carbohydrate antigen 19-9 levels showed no substantial difference between the benign and malignant variants.
CONCLUSIONS: The presence of diabetes, large tumors (> or = 5 cm), marked dilatation of the main pancreatic duct (> or = 10 mm), main pancreatic duct type, and large mural nodules (> or = 10 mm) is strongly suggestive of a malignant variant of the MHST.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app